India Pharma Outlook Team | Monday, 23 March 2026
.png "Sun Pharma Launches Semaglutide Injection in India; Boosts Drug Access")
Sun Pharmaceutical Industries Limited has rolled out its semaglutide injection in India under the brands Noveltreat and Sematrinity, widening access to treatments for type 2 diabetes and chronic weight management.
The launch comes just days after the patent expiry of semaglutide, triggering intense competition across the Indian pharma sector. Noveltreat is designed for chronic weight management, prescribed alongside diet and exercise, and is available in five strengths.
Sematrinity targets adults with poorly controlled type 2 diabetes, offered in two strengths. Weekly treatment costs range from INR 900–INR 2,000 for Noveltreat and INR 750–INR 1,300 for Sematrinity, positioning them as more affordable semaglutide treatment options in India.
Also Read: Indian Pharma Companies Launch Generic Semaglutide Post Patent Expiry
The company said it aims to improve patient access while supporting adherence through a dedicated care program. Both therapies use pre-filled pen devices for accurate dosing. Noveltreat includes a concealed needle system to reduce anxiety, while Sematrinity features a multi-dose dial for flexible use.
The broader semaglutide launch in India has drawn multiple players. Companies such as Dr. Reddy's Laboratories, Zydus Lifesciences, Natco Pharma, Alkem Laboratories, and Torrent Pharmaceuticals have introduced their own versions, while others entered through licensing deals.
Pricing has become the key battleground. Monthly diabetes therapy using disposable pens is mostly priced at INR 4,200–INR 5,200, though Alkem has undercut the market at around INR 2,000. Reusable pens and vial formats offer even lower-cost alternatives, expanding reach among price-sensitive patients.
Analysts estimate the Indian semaglutide market could exceed INR 12,000 crore over five years, driven by rising obesity and diabetes rates. However, while innovation in delivery formats continues, pen-based therapies are expected to dominate due to patient preference.
.jpg)
.jpg)
